BeiGene, Ltd. Interest Expense 2011-2026 | BGNE

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense BeiGene, Ltd.

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-42.6 M	-12.6 M	308 M	-224 M	15.9 M	37.5 M	7.17 M	1.99 M	11.5 M	-972 K	1.22 M	600 K	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
308 M	-224 M	8.65 M

Quarterly Interest Expense BeiGene, Ltd.

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-19 M	8.17 M	3.95 M	-	11.3 M	-12 M	1.76 M	-	337 M	-63.8 M	18.3 M	-	-126 M	-130 M	12 M	-	31.5 M	-867 K	-4.12 M	-	5.71 M	20 M	3.68 M	-	-1.82 M	-878 K	1.73 M	-	1.58 M	75 K	729 K	-	1.1 M	-475 K	913 K	-	284 K	141 K	204 K	-	300 K	273 K	267 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
337 M	-130 M	3.1 M

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Altimmune ALT	-190 K	$ 3.5	4.64 %	$ 308 M	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
Ascendis Pharma A/S ASND	80.6 M	$ 221.52	-0.16 %	$ 5 B	Danmark
Heron Therapeutics HRTX	1.34 M	$ 0.8	2.5 %	$ 133 M	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
AgeX Therapeutics AGE	4.9 M	-	-10.17 %	$ 12.2 K	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
Aileron Therapeutics ALRN	685 K	-	10.36 %	$ 9.8 M	USA
Avenue Therapeutics ATXI	294 K	-	-52.27 %	$ 4.45 M	USA
Adverum Biotechnologies ADVM	8.23 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	432 K	-	2.71 %	$ 14 M	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Immunovant IMVT	471 K	$ 24.27	5.61 %	$ 3.68 B	USA
Incyte Corporation INCY	25.1 M	$ 90.82	0.04 %	$ 17.7 B	USA
Atreca BCEL	3 K	-	-11.76 %	$ 5.79 M	USA
BioDelivery Sciences International BDSI	-6 K	-	-4.8 %	$ 255 M	USA
InMed Pharmaceuticals INM	431 K	$ 0.79	-3.52 %	$ 1.93 M	Canada
INmune Bio INMB	2.28 M	$ 1.23	5.13 %	$ 22.1 M	USA
Inovio Pharmaceuticals INO	1.22 M	$ 1.57	-0.95 %	$ 34.8 M	USA
Innate Pharma S.A. IPHA	566 K	$ 1.34	14.26 %	$ 235 M	France
Calithera Biosciences CALA	2.65 M	-	-10.95 %	$ 876 K	USA
Cara Therapeutics CARA	3.59 M	-	-3.03 %	$ 260 M	USA
ChemoCentryx CCXI	2.7 M	-	-	$ 3.74 B	USA
Checkpoint Therapeutics CKPT	344 K	-	-	$ 169 M	USA
Clovis Oncology CLVS	444 K	-	-7.23 %	$ 13 M	USA
Inventiva S.A. IVA	12.2 M	$ 6.09	5.36 %	$ 138 M	France
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Compugen Ltd. CGEN	281 K	$ 2.13	1.91 %	$ 199 M	Israel
KalVista Pharmaceuticals KALV	4.81 M	$ 16.93	-0.41 %	$ 841 M	Britain
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
CorMedix CRMD	34.3 K	$ 6.35	1.6 %	$ 457 K	USA
Arbutus Biopharma Corporation ABUS	459 K	$ 4.33	2.12 %	$ 719 M	Canada
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA